Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coherent (COHR) : Anyone else holding? -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (405)	1/19/1998 10:02:00 PM
From: Dan Packer	Read Replies (1) \| Respond to of 788

<<Price/Cash flow valuations would make sense if spending for Acquistions/R&D were the norm and Retained earnings were near Nil.>> Help me out, I don't know what you mean by 'norm'. My observation was that so long as COHR can make more money than they need for cost type expenses, the business will continue to grow shareholder equity. It will be reflected in share price ultimately. I'm ignorant about TA. I like their market position, and I like their cash generation. Dan